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ABSTRACT Atopic dermatitis (AD) is a chronic, inflammatory, pru-
ritic skin disease with increasing prevalence. The etiopathogenesis of 
atopic dermatitis is multifactorial and involves a complex interplay of 
environmental and genetic factors that induce derangements in the 
structure and function of the epidermal barrier and immune system. 
Due to great heterogeneity of etiopathogenesis, there is also great 
variability of clinical presentation, and diagnosis can sometimes be 
challenging and difficult. Diagnosis mostly relies on clinical features 
and laboratory tests, but morphology alone cannot reliably establish 
the diagnosis, so the spectrum of features associated with AD must 
be considered. Traditionally, patients with AD have been separated 
into two different subgroups, i.e. intrinsic and extrinsic. Today, most of 
authors prefer the outside to inside and back to outside hypothesis, 
suggesting that the primary disorder lies in epidermal structure and 
function, resulting in inflammation and immunological downstream 
activation which further provokes secondary barrier abnormalities. In 
this review, we discuss the structure and function of the epidermal 
barrier and the role of impaired barrier function in etiopathogenesis 
of atopic dermatitis.
KEy woRDS: atopic dermatitis, skin barrier, atopic barrier, filaggrin, 
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INTRoDUCTIoN
Atopic dermatitis (AD) is a chronic, inflammatory, 
pruritic skin disease with increasing prevalence (af-
fecting 15-30% of children and 2-10% of adults) (1-
4). It is considered to be the first step in the “atopic 
march” that can progress to asthma (AA) and allergic 
rhinitis (AR) (5). Etiopathogenesis is multifactorial 
and involves a complex interplay of environmental 
and genetic factors that induce derangements in 
the structure and function of the epidermal barrier 
and immune system (6). Due to great heterogeneity 
of etiopathogenesis, there is also great variability of 
clinical presentation and diagnosis can sometimes be 
challenging and difficult (7). Diagnosis mostly relies 
on clinical features and laboratory tests, but mor-
phology alone cannot reliably establish the diagno-
sis, and the spectrum of features associated with AD 
must be considered. Several sets of diagnostic crite-
ria for AD have been proposed and validated; most 
clinician traditionally use Hanifin and Rajka’s criteria, 
but full agreement amongst clinicians and uniformity 
of criteria are still lacking (8,9). Traditionally, patients 
with AD have been separated into two different 
96 ACTA DERMATOVENEROLOGICA CROATICA
subgroups, i.e. intrinsic and extrinsic. The extrinsic 
subtype presents with allergic sensitization to an ex-
ternal antigen with subsequent allergen-specific im-
munoglobulin E (IgE) production; the intrinsic variant 
is found in patients with all clinical features of AD but 
no detectable allergen-specific IgE. These subtypes 
may actually represent different stages of evolution 
based on the relative degree of sensitization. AD in 
infancy is thought to begin as “intrinsic”/non-allergic 
dermatitis, and over time it progresses to “true” atopy 
in the majority of cases via allergen exposure through 
what is being increasingly widely recognized as a pri-
marily defective epidermal barrier function (6,10). 
Etiopathogenesis of AD is extremely complex, and 
several hypotheses have been advanced (6). Tradi-
tionally, it was thought that the primary pathogenic 
mechanism of AD was initiated by immune dysfunc-
tion leading to a T helper 2 (Th2) cytokine imbalance, 
increased inflammation, and secondary disruption of 
the epidermal barrier, usually referred as the inside to 
outside hypothesis (11). Recently, after very impor-
tant findings on filaggrin (FLG) and its enormous im-
pact on the structure and the function of the epider-
mal barrier, there is new emerging evidence suggest-
ing that a primary defect in the stratum corneum (SC) 
plays a major role in driving the pathogenesis of AD, 
leading to sustained cytokine release, recruitment 
of pro-inflammatory molecules, and stimulation of 
a Th2 response. This is usually called the outside to 
inside hypothesis (11-13). Today, most authors prefer 
the outside to inside and back to outside hypothesis, 
suggesting that the primary disorder lies in epidermal 
structure and function, resulting in inflammation and 
immunological downstream activation which further 
provokes secondary barrier abnormalities (11,12). 
EPIDERMAL BARRIER
The epidermal barrier (EB) is the first line of defense 
against the environmental influences and prevents wa-
ter loss and preserves electrolyte balance. The epider-
mis generates a set of protective/defensive functions 
mediated by its unique differentiation end product, the 
stratum corneum (SC) (11). The permeability barrier re-
sides in the SC, which is a multilayered tissue composed 
of flattened anucleate corneocytes surrounded by mul-
tiple lamellar sheets enriched in ceramides (CER), cho-
lesterol (CHOL) and free fatty acids (FFA), surrounded 
by a cell envelope composed of cross-linked proteins, 
the corneal envelope (14,15). Nucleated cells with cyto-
skeleton and tight and gap junctions contribute to the 
physical barrier. The permeability barrier retards trans-
cutaneous water loss, microbial invasion, and entry of 
allergens and irritants. Another very important func-
tion is providing mechanical support (14).
The chemical barrier is formed by lipids, “acid man-
tle”, antimicrobial peptides secreted by keratinocytes 
(KC), and the FLG protein that aggregates keratin 
filaments and produces natural moisturizing factors 
(NMF). The so called “acid mantle” is provided by free 
fatty acids (FFA), lactic acid from sweat, and urocanic 
acid, a degradation product of FLG (14). These com-
ponents act together in ensuring normal keratiniza-
tion and lipid synthesis, providing antimicrobial pro-
tection, and proper hydration of the skin (14). Hydro-
fobic lipids within the extracellular domain inhibit the 
outward movement of the water. Lipids are delivered, 
like their precursors, through secretion of the epi-
dermal lamellar body (LB). As the SC is formed, these 
bodies deliver lipid constituents, lipid precursors, and 
enzymes required to generate CER and FFAs required 
for their organization into mature membrane struc-
tures (15). Additionally, proteases and their inhibitors 
derive from LB and orchestrate the orderly digestion 
of corneodesmosomes, allowing corneocytes to shed 
invisibly at the skin surface (15,16). The immunologi-
cal barrier is closely linked to innate immunity of the 
skin. This results from complex interaction of the 
physical barrier, several immunologically active cell 
types, action of antimicrobial peptides, cytokines and 
encoded proteins called patern recognition recep-
tors (PRR) (14,17). Cells involved in innate immunity 
are KCs, dendritic cells, Langerhans cells, neutrophils, 
and natural killer cells (17,18). Immune response and 
inflammation will be discussed further in the text.
BRoAD BARRIER FAILURE IN AToPIC DER-
MATITIS IS A DRIVER FoR CHRoNICITy oF 
DISEASE
Dysfunction of the skin barrier in AD is the result 
of a complex interplay between the patient’s geno-
type, environmental factors, and inflammation activ-
ity (11,12,19,20). Barrier abnormalities can be roughly 
characterized into inherited barrier abnormalities, the 
group of exogenous and endogenous stressors with 
further aggravation of barrier function, and impaired 
antimicrobial defense with further compromised 
barrier function (12). There is a complex interaction 
between genetic influences and exogenous and en-
dogenous factors.
Recently, the focus has been on the role of genetic 
abnormalities which lead to key structural defects in 
EB, since 80-90% of all AD have a genetic background. 
The genes affected in AD include those encoding the 
FLG protein, serin proteases (SP), and protease in-
hibitors (12,14). Although mutations in FLG are best 
known, mutations in other members of the fused S-
100 family of proteins (hornerin and filaggrin 2, the 
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cornified envelope precursor (i.e. SPRR3), mattrin, 
which is encoded by TMEM79 and regulates the as-
sembly of lamellar bodies, SPINK5, which encodes 
the serine protease inhibitor lymphoepithelial Kazal-
type trypsin inhibitor type 1, and the fatty acid trans-
port protein 4 have all been linked to AD (21). These 
abnormalities often only predispose to AD, and ad-
ditional acquired stressors that further compromise 
barrier function, such as psychological stress, low 
ambient humidity, or high-pH surfactants are often 
required to trigger the disease (21). Th2 cytokines can 
also compromise barrier function by downregulating 
expression of multiple epidermal structural proteins, 
lipid synthetic enzymes, and antimicrobial peptides. 
All of these inherited and acquired abnormalities 
converge on the lamellar body secretory system, pro-
ducing abnormalities in lipid composition, secretion, 
and/or extracellular lamellar membrane organization, 
as well as antimicrobial defense (21).
The mutation of the FLG gene (FLG mut) has the 
greatest influence, and today the majority of authors 
put it at the center of the etiopathogenesis. Filaggrin 
(FLG) was named by the late Peter Steinert, and its 
gene, among other proteins involved in terminal dif-
ferentation, is located on chromosome 1q21, called 
the epidermal differentiation complex (13). The FLG 
gene (FLG) encodes for important multifunctional 
structural and functional protein of the epidermis. The 
name “filaggrin” is derived from the term “filament-
aggregating protein”. Loss-of-function mutations, in 
one or both alleles, result in reduced or completely 
absent levels of epidermal FLG (22,23). Loss of func-
tion mutations in FLG are the major risk factor for de-
veloping AD (24). Not all AD can be explained by FLG 
mutations however, since only 40% of patients with 
AD have this mutation, and not all individuals with 
FLG mut will develop AD (24-26). FLG mut alone does 
not suffice, and this fact is clearly shown in ichtyosis 
vulgaris where FLG mut is found in one or both alleles, 
but inflammation does not occur (12,27). Recent find-
ings report a reduced skin barrier function irrespec-
tive of FLG genotype, suggesting the importance of 
additional factors for an impaired skin barrier in AD 
beside the impact of FLG mutation (28,29). About 
10% of the general population in Northern Europe 
are heterozygotous mutation carriers, while 0.1% are 
homozygotous (12,30). Data for Southern Europe are 
scarce, but indicate that these mutations are rare or 
even absent (31-34). However, prevalence of FLG mut 
is much higher in patients with AD, and prevalence of 
this mutation is 25-50% in patients with AD in North-
ern Europe (24). Some authors view the north-to-
south gradient in observed prevalence of FLG mut as 
evolutionary, speculating that these mutations have 
evolved due to low exposure to the sun and that this 
might be closely related to vitamin D in lightly pig-
mented Northerners. It is also known that NMF is re-
sponsible for UV protection. Another hypothesis and 
potential explanation is increased penetration of mi-
croorganisms as an in vivo mechanism of vaccination 
(13,35-37).
FLG loss-of-function mutations show population 
specificity (34). Since the discovery of the first two 
loss-of-function mutations (R501X and 2282del4) 
in 2006, these two mutations, along with the less 
prevalent S3247X and R2447X, have been studied 
and are present in 7-10% of the Caucasian popula-
tion of Europe (24,35,41). More than 20 other rare or 
family-specific mutations have been discovered in 
white European ancestry (35). The population speci-
ficity indicates that they have arisen after one popu-
lation has become split away from another (35). The 
Asian population has their own mutation spectra 
(35,38,39). The prevalence of FLG null-mutations var-
ies across Europe, but R501X and 2282del4 are the 
two most common mutations and they have consis-
tently shown significant association with AD across 
the continent, with the exception of the Italian popu-
lation (32,33,35,40). Full sequencing of FLG in the Ital-
ian population identified only 3 additional mutations 
and no association with AD (32,33). 
In those patients in whom AD is linked to FLG 
mutation, there is a genotype-phenotype correlation 
(42-44). Prevalent and low-frequency null-mutation 
in FLG is associated with early onset and persistent 
atopic eczema (42). FLG haploinsufficiency is highly 
penetrant and is associated with increased severity 
of eczema (43). The phenotype of early onset (before 
2 years of age), persistent, and severe eczema has 
shown the strongest and most significant statistical 
association with the combined FLG null phenotype, 
with an odds ratio of up to 7.7 (44-46). However, the 
milder phenotype has also shown a statistically sig-
nificant association (44,47). Beside loss-of-function 
mutation of FLG, there is another important genetic 
influence on FLG levels (12). The FLG gene is a repeti-
tive gene and shows intragenic copy number varia-
tions (CNV), with the number of repeats between 10 
to 12 (48). All reported FLG null-mutations are non-
sense or frameshift mutations, resulting in truncation 
of the profilaggrin molecule. FLG encodes for profil-
aggrin (ProFLG), polymers released from keratohyalin 
granules of stratum granulosum and proteolitically 
cleaved into 10-12 identical FLG monomers by en-
zymes. The liberated FLG monomers aggregate kera-
tin filaments into tight bundles, resulting in collapse 
and flattening of corneocytes. FLG and other epider-
mal differentiation-linked proteins are crosslinked 
Jurakić Tončić and Marinović Acta Dermatovenerol Croat
Epidermal barrier function in AD  2016;24(2):95-109
98 ACTA DERMATOVENEROLOGICA CROATICA
into the cornified envelope by transglutaminases. 
Keratin 1 and 10 associate with FLG and its degrada-
tion products and constitute the bulk of cytosol of 
the anucleate corneocytes (KC) (12). 
Besides structural function and mechanical 
strength, FLG has another very important function. 
As KCs move apically, FLG detaches from the corni-
fied envelope, followed by degradation into constitu-
ent aminoacids, glutamine, arginine, and histidine 
and into their deiminated metabolites (12,49-51). 
Histidine is a substrate for histidase which generates 
trans-urocanic acid (tUCA), which is a major ultravio-
let B (UVB)-absorbing epidermal chromophore that 
also contributes to the acid mantle of the skin (49). 
Glutamine is converted into pyrrolidone-5-carboxilic 
acid (PCA), a major component of “natural moisturiz-
ing factors” (NMF) of the SC and therefore a potent 
humectant, accounting for much water retention in 
the SC (49-51). 
Another function of NMF is acidification, or, more 
precisely, maintaining proper pH values of the skin. 
Acidification is very closely connected to the antimi-
crobial function of the barrier as well as to proteolytic 
activity and release of proinflammatory cytokines 
(12,52). A loss of function mutation in FLG is strong-
ly associated with an elevated pH of the SC surface, 
which might negatively influence SC lipid production, 
activity of various proteases involved in inflamma-
tory processes, and desqumation and antimicrobial 
defense (12). Therefore, FLG deficiency affects epider-
mal protein expression and organization (12,53). 
There is also evidence of environmental and inflam-
mation-driven reductions in levels of epidermal FLG, 
and not only due to genetic reasons (12). It is known 
that monomeric FLG is hydrolyzed in a humidity-sen-
sitive fashion as environmental humidity declines, fol-
lowing a rapid shift from a humid to a dry environment 
(54). Children with AD linked to FLG mut more frequently 
have dermatitis on air-exposed areas when compared 
to the wild type (55). UVB radiation is another climatic 
and environmental influence, single dose of UVB expo-
sure leads to downregulation of FLG expression (12,56). 
Beside climatic influence, exposure to water and irri-
tants also reduces FLG levels (57). Mechanical distur-
bance of the barrier, such as scratching as a result of 
intense pruritus in AD, also downregulates FLG expres-
sion. Moreover, further barrier disruption in the chronic 
stages of AD through mechanical scratching not only 
perpetuates, but alters the response to a mostly Th1 
type (12). Topical therapy can also have an impact on 
the expression of epidermal FLG. It is interesting that 
prolonged use of topical corticosteroids, but not topi-
cal tacrolimus, reduces epidermal FLG (21,58,59).
Other genes can be affected and have important 
influence on epidermal barrier, such as genes that 
upregulate serin proteases (SPs). Genetic defects due 
to gain of function mutations in the kalikrein 7 gene 
encoding serin proteases up-regulate serin proteases 
(SPs) (14). Increased activity of SPs degrades desmo-
somes, lipid-processing enzymes which results in 
decreased production of ceramides (12). It also acti-
vates the protease activator type 2 receptor (PAR-2) 
by direct cleavage and inducing its signal cascade, 
resulting in downregulation of lamellar body secre-
tion and increased production of interleukin 1 alpha 
(IL-1α) and interleukin 1 beta (IL-1β) from corneocytes 
leading to inflammation (60,61). Protease inhibitors 
(PIs) are another important part of the balance due 
to the fact that these inhibitors inhibit the function 
of proteases (14). Cystatin A is a cystein PI secreted 
by sweat glands to inhibit the degradation by exoge-
nous (microbial) proteases. Gene mutations for this PI 
has been found in patients with AD (14,19,60,62). The 
best example of impaired protease inhibitor function 
is in Netherthon syndrome, which is characterized 
with severe eczema, mucosal atopy, and severe food 
allergies. This syndrome is linked to loss-of-function 
mutation in gene SPINK-5 which encodes for LEKTI 
(lymphepithelial Kazal type inhibitor), which is also a 
protease inhibitor (14,63,64).
INFLAMMATIoN AND THE RoLE oF  
IMMUNE SySTEM 
Inflammation is another independent factor that 
reduces levels of the FLG and NMF (12). This occurs in-
dependently of FLG mut status (65,66). Inflammation 
results from increased SPs activity, which activates 
the primary cytokines, IL-1 α, and IL-1β from their pro-
forms stored in KCs (20). Increased protease activity 
is the result of elevated pH, and this is typically the 
first step in a cascade of inflammation (65-68). The 
second step is sustained antigen ingress through the 
defective barrier, leading to Th2-dominant infiltrate 
(11). Certain antimicrobial antigens are preferentially 
associated with AD and show a propensity to trigger 
AD, especially in FLG-deficient patients (21). These 
microbial antigens activate SP activity and further 
damage the barrier (more details in the section on 
antimicrobial function).
Despite current accumulating evidence on barri-
er-initiated pathogenesis of AD, there is evidence on 
other mechanisms whereby Th2 generated cytokines 
worsen AD (11,20,65,70). The key Th2 cytokines, IL-4, 
and IL-13 cause further aggravation of AD by causing 
the following negative effects: IL-4 causes inhibition 
of ceramide synthesis, inhibition of KC-differentia-
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tion-linked proteins (loricrin and FLG), and decreased 
desmoglein-3 expression with compromised SC in-
tegrity (65,70-72).
The skin is immunologically active and the skin 
barrier has an immunological function. One of the 
key elements in the immunological barrier are PRRs. 
They can be transmembrane/intracellular recep-
tors and include a group of toll-like receptors (TLR), 
through which KCs sense microbial invasion and in-
jury (13,14,73). Activation of TLRs on KCs can upregu-
late proinflammatory cytokine expression via the ac-
tivation of NF-ĸB (73). Cells secrete cytokines, such as 
TNF-α, and interleukins such as IL-6 and IL-1α, which 
results in stimulation of cell proliferation and lipid 
synthesis (13,14,73). It is interesting that acute bar-
rier disruption causes an increase in cytokines crucial 
for barrier repair, but chronic disruption, on the other 
hand, leads to inflammation and epidermal prolifera-
tion (13,14).
Although the role of the innate immune system 
has not yet been elucidated, it is known that activa-
tion of innate immune receptors results in the release 
of various inflammatory mediators derived from KCs 
which probably decrease FLG expression (75,76). 
Therefore, inflammation causes decreased FLG ex-
pression, regardless of FLG mutation status. 
One of the hallmarks of the extrinsic variant of AD 
is elevated serum IgE. Serum IgE acts as an autoanti-
body, but it is still not known whether it targets FLG 
as well; it is however known that IgE autoreacts with a 
variety of KC-antigens (77). Autoantigens are released 
from damaged tissue triggered by mechanical injury/
scratching (78).
It recently was discovered that the gene MAP-17 
is associated with the T-helper cell cytokine-induced 
down regulation of FLG transcription in human KCs 
(79). Various cytokines such as IL-4, IL-17, IL-22, IL-25, 
and IL-31 can upregulate the MAP-17 gene, which fur-
ther down-regulates FLG synthesis, CER production, 
and cell-to-cell adhesion (80-84). This provides a link 
between altered FLG and lipids in patients with AD.
RoLE oF LIPIDS
The structure of the barrier is closely related to its 
function. FLG has an enormous impact on the barrier, 
but a second very important cause of barrier altera-
tion is change in the structure and composition of 
SC lipids. The permeability barrier resides in the SC 
which is multilayered tissue composed of flattened 
anucleate corneocytes surrounded by multiple lamel-
lae sheets enriched in ceramides (CER), cholesterol 
(CHOL), and free fatty acids (FFA) (15). Hydrofobic lip-
ids within the extracellular domain have a significant 
role because they inhibit the outward movement of 
the water (15). Lipids are delivered as their precursors 
through secretion of the epidermal lamellar body 
(LB). As the SC is formed, LB deliver lipid constituents, 
lipid precursors, and enzymes required to generate 
CER and FFAs that are required for their organization 
into mature membrane structures (15). Additionally, 
proteases and their inhibitors derive from LB and or-
chestrate the orderly digestion of corneodesmo-
somes, allowing corneocytes to shed invisibly at the 
skin surface (15,16,85). CER are the main components 
of the multilayered lamellar bilayers between the 
corneocytes and thus the key factor in water reten-
tion and overall integrity of the barrier (86). It is well 
known that CER, with CHOL and FFA in a ratio of 3:1:1, 
are the most prominent group of physiological lipids 
and show alterations in skin of patients with AD. Dif-
ferent classes of CER differ in the length of the free 
fatty acid chain and sfingosin base. To date, 12 CER 
subclasses have been identified in humans, showing 
a wide chain length distribution (87-89). CER play a 
crucial role in the lipid organization due to their char-
acteristic molecular architecture (90). In healthy SC, 
lipids form two lamellar phases with repeat distances 
of 6 nm and 13 nm, called the short periodicity phase 
and long periodicity phase (91). Lamellar lipids have 
a dense orthorhombic lateral organization, although 
a subpopulation of lipids can be densely packed in 
a hexagonal organization (92,93). Several studies on 
patients with AD reported reduction in total cera-
mids and reduction in long-chain CER and FFA (94-
97). This substitution of shorter chain FFA results in 
lipid disorganization that likely further compromises 
barrier function (87,98). The relative chain length of 
CER is shorter and this correlates with an altered lipid 
organization and barrier function. This effect is FLG 
mut independent, but is associated with the levels 
of NMF (87). This fact suggests that FLG (genotype), 
NMF (phenotype), and other (translational and en-
vironmental) factors can influence NMF levels (87). 
Copy number variation of FLG and interleukin levels 
can probably downregulate FLG expression (70). NMF 
levels lead to elevated pH levels which may affect en-
zymes involved in CER synthesis and proteolytic ac-
tivity (87,99-101). Changes in lipid composition and 
organization are observed in lesional skin, but also in 
nonlesional skin where increased levels of extremely 
short C34 chains were found. It is also reported that 
CER chains length is an important determinant of lat-
eral lipid organization (87,97). These changes in CER 
chain length distribution correlate with changes in 
lipid organization, skin barrier function, disease sever-
ity, and levels of NMF. Therefore, chain length of CER 
is an important factor in skin barrier dysfunction. It is 
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suggested that this increase in short chains is due to a 
misbalance in the activity of some of the members of 
the elongase family, since the elongase family plays 
an important role in the elongation of fatty acids in 
the epidermis (98). Some other studies showed that 
the CER composition and chain length, rather than 
the ratio between lipid classes, plays a major role in 
the increased transepidermal water loss (TEWL) in 
nonlesional skin (102). 
According to some authors, FLG deficiency also 
affects the delivery of lipids (12). Due to cytoskeletal 
abnormalities, loading into LB is partially compro-
mised, resulting in some KCs being deficient in LB 
(103). This could reduce the normal quantities and or-
ganization of the extracellular lamellar bilayers (104). 
This provides a link between FLG and lipid composi-
tion of the epidermis.
Th2 cytokines can also compromise barrier func-
tion by downregulating expression of multiple epi-
dermal structural proteins, lipid synthetic enzymes, 
and antimicrobial peptides (68). All of these inherited 
and acquired abnormalities converge on the lamellar 
body secretory system, producing abnormalities in 
lipid composition, secretion, and/or extracellular la-
mellar membrane organization, as well as antimicro-
bial defense (68). It has been recently shown that mu-
tations in the genes FATP4 (encodes for FATP4- fatty 
acid transporter in the suprabasal layer of epidermis) 
and Tmem79 (encodes for a component in the lame-
lar granule secretory system) both associate with an 
increased risk of AD. These are both independent of 
FLG mut and can emphasize the importance of altered 
lipid production and secretion in the pathogenesis of 
AD (12,105,106). 
Inflammation is another significant factor that 
can influence lipid status (12). In the chronic phase 
of AD, γ-IFN down-regulates two fatty acid elongases 
(ELOVL1 and ELOVL4) required to generate the very 
long chain N-acyl fatty acids in CER and FFA (98). In 
this way, inflammation negatively influences lipid 
composition. 
pH oF THE BARRIER AND PRoTEASE  
ACTIVITy
Maintenance of adequate pH is very important for 
adequate skin barrier and function by preventing un-
necessary activation of serin proteases (85,99,101). As 
already mentioned, reduction of the epidermal FLG 
results in reduction of its NMF, which is responsible 
for maintaining acidic pH. There is an allele dose-de-
pendent effect, and homozigotous FLG mut carriers 
usually have the highest pH levels (50,51). There is 
a compensatory mechanism due to upregulation of 
Na+/H+ antiporter (NHE-1) which seems to counter-
act this pH increase, which may explain why elevated 
pH is not always seen in all FLG mut carriers (107). pH-
sensitive proteases are activated following the pH 
increase (12). This causes premature degradation of 
corneodesmosomes and compromises intercellular 
connections and activates IL-1α and IL-1β (108,109). 
The most compelling evidence comes from Nether-
thon syndrome (12,108). Protease activation impairs 
CER production and likely stimulates Th2 inflamma-
tion in AD (12). In addition to the protease effect of 
kalikreins, they also bind to protease activated re-
ceptors type 2 (PARS2) which downregulate lamel-
lar body secretion and initiate a cascade of innate 
inflammatory responses, including activation of thy-
mic stromal lymphoprotein (TSLP) from KCs. TSLP is 
a masterswitch for initiation of Th2 inflammatory re-
sponses (12,108,110,111). TSLP is produced by KCs, 
and secretion is induced by exposure to allergens, 
microorganisms, or mechanical injury (111-113). 
TSLP has an important role in the etiopathogenesis 
of itch, since it induces cutaneous nerves to release 
neuropeptides causing itch, with the consequence of 
scratching and further damage to the barrier and sec-
ondary superinfection (114).
INCREASED ALLERGEN PENETRATIoN 
AND ENHANCED IMMUNE REACTIVITy
FLG deficiency permits increased allergen pen-
etration and enhances immune reactivity (12). FLG-
null mouse is a model for ichtiosis vulgaris without 
AD, and these mice show accelerated allergen pen-
etration through the SC as well as enhanced contact 
hypersensitivity response (115,116). In such cases, 
double allele mutations in FLG cause inherited skin 
barrier dysfunction (106). Another piece of evidence 
comes from the “flaky-tail” mouse with matted muta-
tion (Tmem 79) which shows spontaneous inflamma-
tion and also increased penetration of allergens as 
well as a low threshold to irritation to allergens and 
skin irritants (116). Allergic sensitization and inflam-
mation causes further exacerbation of the barrier def-
icit, which can be observed in the elevation of TEWL. 
Exposure to allergens or other stressors activates the 
inflammasome, protease, and downstream immune 
mechanisms (12). Some microorganisms can secrete 
and activate serine proteases and cause proteolitic 
damage to the barrier, but also cause release of active 
forms of IL-1α and IL-1β from KCs and initiate inflam-
mation (117,118). Additionally, in conditions of FLG 
deficiency, stimulation of TLR 3 enhances production 
of TSLP (119,120). These findings suggest a link be-
tween FLG deficiency, Th2 promotion, and systemic 
disease (12,120). These observations on mouse mod-
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els are yet to be confirmed in humans, but results 
from metaanalysis done in 2009 show that patients 
with AD and with FLG mutations have increased risk 
of sensitization to allergens and development of 
asthma, allergic rhinitis, and food allergy (121). 
ANTIMICRoBIAL DEFENCE
Another important function of the skin barrier is 
the antimicrobial function, which strongly encour-
ages the growth of nonpatogenic flora (122). Healthy 
skin is colonized by large numbers of microorgan-
isms, which are classified into resident and transient 
flora (123). Resident flora colonizes the skin in pro-
portionally constant numbers and includes coagu-
lase-negative staphylococci (S. epidermidis, S. hemo-
lyticus, S. hominis). Transient flora is caused by con-
tact of the skin with external objects. Staphyloccocus 
aureus (SA) is not a member of resident flora (123). It 
has prevalence of approximately 5% in healthy popu-
lation (124). More than 90% of patients with AD have 
SA on their lesional, and 30-100% on nonlesional skin 
(125,126). Permeability and antimicrobial dysfunc-
tion are well-known features of AD and are co-regu-
lated and interdependent (19,61,67,68,127). Failure of 
the permeability barrier favors secondary infection, 
and secondary infection further compromises the 
barrier (19). Again, FLG plays an important role (12). 
FLG seems to protect against colonization of certain 
microorganism (12). Staphylococcus aureus (SA) has 
an important role in etiopathogenesis of AD. The skin 
of patients with AD exhibits a striking susceptibility 
to colonization and infection with SA (123). Patients 
with AD have the highest counts of SA on lesional 
skin, but often colony counts are elevated on even 
nonlesional/clinically normal skin (128). There is an 
extreme difference between lesional and nonlesional 
skin, and these counts differ by 100 to 1000 times 
(123,129). Indeed, SA colonization is both a cause 
and a consequence of allergic skin inflammation 
(123). Impaired barrier in AD predisposes to patho-
gen colonization not only due to increased pH, but 
also because of reduced levels of FFA and ceramide 
metabolite sfingozine which exhibits potent antimi-
crobial activity (19, 130,131). Surface proteins on SA 
downregulate epidermal FFA production, therefore 
aggravating permeability and antimicrobial function 
(132). Adherence of SA is increased in patients with 
AD due to injury of the skin barrier which leads to ex-
posure of extracellular matrix adhesins for SA, epider-
mal and dermal laminin, and fibronectin (133,134). 
Fibronectin in combination with plasma exudation 
of fibrinogen allows SA to bind to the skin (133,134). 
Scratching further damages the barrier and causes 
cytokine release with upregulation of the expression 
of adhesins (135). There is evidence that Th2 inflam-
mation, or, more precisely, IL-4 plays important role 
in the enhancement of SA binding by inducing the 
production of fibronectin (134,136). Alteration of lip-
id composition is another contributing factor due to 
decrease in ceramides which leads to dry and cracked 
skin and predisposes to colonization (137). SA stimu-
lates hydrolysis of CER by bacteria-produced cerami-
dases (138). Sphingosine exerts a potent antimicro-
bial effect in normal conditions, but, as a result of 
reduced activities of acid ceramidases and decreased 
levels of CER in general, the levels of sphingosine are 
also reduced (139). Normal FLG expression increases 
sphingomyelinase secretion (140).
Another important reason for SA colonization is 
defective innate immune response (122,123,132). 
There are 2 classes of endogenous antimicrobial 
petides; β-defensins and cathelicidins, produced by 
KCs with antimicrobial effects against bacterial, fun-
gal, and viral antigens (123). Antimicrobial peptides 
are delivered to SC intercellular domains via secretion 
of LB contents (19,141-143). Some of these antimicro-
bial peptides are constitutionally produced, while 
others (HBD-2, LL-37) are induced by TNF-α following 
skin inflammation or injury (123). These endogenous 
antimicrobial peptides are essential for defending the 
skin against bacterial infection (144). Members of two 
key families of antimicrobial proteins, the human cat-
helicidin product (hCAP), LL-37, and human β-defen-
sins (hBD) 2 and 3 are downregulated in Th-2-depen-
dent fashion (145-147). Fragments of hCAP and hBD3 
exhibit potent antistaphylococcal activity (147).
In 70% of all patients with AD, non-toxin produc-
ing-SA strains are replaced with enterotoxin-produc-
ing strains and exacerbate AD via 3 mechanisms: 
these strains cause more frequent clinically apparent 
reactions; some toxins stimulate pruritus and produc-
tion of specific IgE; and finally, some toxins act as su-
perantigens by stimulating T- and B-cell production 
and switching to allergen-specific or superantigens 
that stimulate IgE production (19,66,122,123,148). 
Staphylococcal superantigens may directly stimulate 
antigen presenting cells and KCs to produce several 
proinflammatory cytokines, such as IL-1, TNF-α, and IL-
12 and contribute to persistence and exacerbation of 
allergic skin inflammation (123,149). They recognize 
and stimulate T cells bearing the specific TCRβ which 
results in massive activation of polyclonal T cells (up 
to 20% of total T cell population) (123). Superantigen-
producing SA strains further exacerbate AD through 
augmentation of IgE production and development 
of specific IgE against SA exotoxins (122). It has been 
reported that T cells stimulated with superantigens 
become resistant to immunosuppressive effect of 
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corticosteroids (123,150). Activated T cells produce 
IL-31 which induces pruritus. It is well known fact that 
infections (such as folliculitis) are also extremely pru-
ritic. Pruritus starts an itch-scratch cycle which causes 
further damages to the barrier and facilitates spread-
ing of the infection (122). Another very interesting 
observation is that SA-α toxin preferentially destroys 
FLG-deficient KCs, so FLG again plays an important 
role (140). FLG breakdown products reduce growth 
rates of SA (151). In general, patients with AD with FLG 
mut have 7-fold increased risk of bacterial infection 
when compared to FLG wild type patients (12,152). 
Some microbes such as SA, dust mites, and scabies 
induce proteolitic activity with cleaving corneodes-
mosomal proteins and FLG, contributing further to 
the cycle of inflammation and pruritus. 
Patients with AD are also prone to viral infections, 
especially to herpes simplex (7,153). Eczema herpeti-
catum (EH) is clinically defined as disseminated her-
pes simplex viruses (HSV) infection which is almost 
exclusively seen in patients with AD (154). Nectin-1 
is an entry receptor for HSV (155). Nectin-1, a cell ad-
hesion molecule belonging to the immunoglobulin 
superfamily, can bind to virion glycoprotein D (gD) 
to mediate entry of HSV. Nectin-1 colocalizes with E-
cadherin at adherens junctions in epithelial cells. The 
disruption of cell junctions can result in the redistri-
bution of nectin-1 (155). Lack of plasmacytoid den-
dritic cells, cathelicidin production, and an abnormal 
IFN-γ response to HSV all contribute to pathogenesis 
of eczema herpeticatum (156-158). The cathelicidin 
peptide LL-37 possesses antiviral activity against HSV 
and demonstrates the importance of variable skin ex-
pression of cathelicidins in controlling susceptibility 
to eczema herpeticum (156). Additionally, serum IgE 
levels might be a surrogate marker for innate immune 
function and serve as a biomarker for determining 
which patients with AD are susceptible eczema her-
peticatum (156).
Hinz et al. showed that patients with AD, recurrent 
HSV infection, and a history of eczema herpeticatum 
had higher serum IgE levels, more severe AD, and a 
higher IgE sensitization profile when compared to a 
group without history of eczema herpeticatum (159). 
It is interesting to point out that staphylococcal α-
toxin increases the HSV load and therefore contrib-
utes to EH (160). A subset of patients with AD is prone 
to disseminated herpes simplex virus (HSV) infection, 
and biomarkers that identify this subgroup are lack-
ing. A recent study has found that the two master 
regulators of innate immune responses IRF3 and IRF7 
are suppressed in this subgroup, suggesting that ab-
normalities of up-stream of IRF3 and IRF7 signal path-
ways (161).
CoNLUSIoNS
FLG has the central role in the etiopatogenesis of 
AD, since FLG deficiency affects epidermal protein 
expression and organization. A loss of function muta-
tion in FLG is strongly associated with an elevated pH 
of the SC surface which might negatively influence 
SC-lipid production, activity of various proteases in-
volved in inflammatory processes, and desquamation 
and antimicrobial defense. Not all patients can attri-
bute their AD to FLG mutations. Up to 40% of patients 
with AD have one or two FLG mutations, and these 
mutations are associated with early onset as well as 
more severe and prolonged disease. Other patients 
with no FLG mutations have other causes of impaired 
barrier. Lipids are another very important determi-
nant of skin barrier. Altered composition and struc-
ture of the lipids has a great impact on the function of 
the barrier. Since many proteolytic enzymes and pro-
tease inhibitors are involved in obtaining the normal 
function and structure of the barrier, there are nu-
merous factors which can be influenced and whose 
function can be altered. All important functions of 
the barrier are a result of the barrier’s structure and 
organization. Except genetic predisposition, where 
FLG mutation has the greatest influence, a many ex-
ogenous and endogenous stressors can further com-
promise the barrier. All traditional, “gold standard” 
therapeutic options today aim at inflammation and 
modulation of inflammatory response. We now know 
that everyday skin care and use of emollients is ex-
tremely important. What kind of emollients patients 
use is also very important, since every local therapy 
has an impact on the barrier. Since the barrier is im-
paired in patients with AD, some local products can 
even worsen and further compromise the barrier. Un-
derstanding the structure of the barrier and complex-
ity of the function is a first step in understanding the 
etiopathogenesis of AD. It seems that every patient 
has AD with their own, unique set of mutations of 
important structural proteins, lipids, and proteolitic 
enzymes and their inhibitors, so it is probably wise to 
determine what kind of impairment of the barrier pa-
tient has and use this information in the therapeutic 
approach. It would be also advisable to take this into 
consideration in everyday life beginning with birth, 
since most of authors today the barrier impairment 
to be the first step in etiopathogenesis, with numer-
ous genetic and environmental impacts. It is likely 
that in future we will apply the lessons from the bar-
rier to create a more complex therapeutic approach. 
Corticosteroids and immunomodulators have an 
impact only on immunological response, but do not 
influence the barrier impairment. The barrier is also 
influenced by psychosociological stress and numer-
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ous exogenous stressors that are common in modern 
life, such as environmental pollution and numerous 
hygiene products which cause further damage to the 
barrier. The rational approach would be aiming at re-
duction of consequences caused by genetics, such as 
FLG mutation and FLG deficiency, since epidermal FLG 
level is not only determined by the mutation itself. Ex-
cept the genetic influence, another important deter-
minant are numerous endogenous and exogenous 
stressors which further diminish barrier function. Lo-
cal therapy can help in breaking the scratch-itch cycle 
and inflammation, since scratching causes mechani-
cal damage to the barrier with the consequence of 
inflammatory response driven by damaged keratino-
cytes. In patients who show lipid aberration, a wise 
approach would be aiming at normalizing ceramide 
chain length distribution. Recently, much effort has 
been made to understand the role of the emollients, 
since their composition and characteristics are a very 
important determinant that can help improve impair-
ment of the barrier. 
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